Datavault AI (NASDAQ: DVLT), a leader in AI-driven data experience, valuation and monetization, and Wellgistics Health Inc., a next-generation pharmaceutical distribution and digital prescription routing company, have signed a non-binding letter of intent to integrate DataVault’s blockchain-enabled PharmacyChain smart contract technology into Wellgistics’ proprietary infrastructure. The collaboration aims to digitize prescription tracking from script to fulfillment, ensuring accurate, transparent and efficient delivery while supporting patient safety and optimized outcomes.
The companies are exploring a revenue-sharing model based on PharmacyChain usage fees, with definitive terms to be determined following further negotiation. This partnership underscores the growing trend of leveraging blockchain technology to enhance supply chain integrity in the pharmaceutical industry. By utilizing smart contracts, the system can automate verification and tracking, reducing the risk of counterfeit drugs and improving compliance with regulatory requirements.
PharmacyChain is designed to create an immutable record of each prescription’s journey, from the prescriber to the patient. This level of transparency is crucial in an industry where medication errors and drug diversion remain significant concerns. The integration with Wellgistics’ digital routing platform could streamline operations for pharmacies, wholesalers, and healthcare providers, potentially lowering costs and improving patient outcomes.
For more details, the full press release is available at https://ibn.fm/dnQ0i. Datavault AI’s technology suite is customizable and offers AI and Machine Learning automation, third-party integration, detailed analytics, and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.datavaultsite.com.
This announcement comes as the healthcare sector increasingly adopts digital solutions to address longstanding inefficiencies. Blockchain’s ability to provide a secure, decentralized ledger makes it particularly suitable for tracking sensitive data such as prescription drugs. The partnership could set a precedent for similar collaborations in the industry, potentially accelerating the adoption of blockchain in pharmaceutical supply chains.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors beyond management's control, as detailed in the company's filings with the SEC. Undue reliance should not be placed on these forward-looking statements.
